Suppression of experimental autoimmune encephalomyelitis by dermatan sulfate.
The effect of dermatan sulfate (DS) on the treatment of Lewis rats with experimental autoimmune encephalomyelitis (EAE) was examined. DS, a sulfated glycosaminoglycan, has been reported to exhibit anticoagulant and fibrinolytic activities. DS treatment (50 mg/kg/day) facilitates recovery from the clinical manifestations of EAE. In this study, the fibrinolytic activity was higher in DS-treated rats than in saline-treated rats. Although the degree of perivascular mononuclear cell infiltration in the spinal cord was not suppressed in DS-treated rats compared to that in saline-treated rats, perivascular fibrin deposition was markedly suppressed in DS-treated rats. These findings suggest that DS would act as an effective therapeutic agent for EAE by preventing fibrin deposition.
Inaba
Y
Y
Department of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Ichikawa
M
M
Koh
C S
CS
Inoue
A
A
Itoh
M
M
Kyogashima
M
M
Komiyama
A
A
D000818:Animals; D000990:Antithrombin III / Q000032:analysis; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D008213:Lymphocyte Activation; D010447:Peptide Hydrolases / Q000032:analysis; D051381:Rats; D011917:Rats, Inbred Lew; D013601:T-Lymphocytes / Q000276:immunology
C046193:antithrombin III-protease complex; D003871:Dermatan Sulfate; D000990:Antithrombin III; D005340:Fibrinogen; D010447:Peptide Hydrolases